Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients
- Authors
- Baek, Han-Sang; Jeong, Chaiho; Shin, Kabsoo; Lee, Jaejun; Suh, Heysun; Lim, Dong-Jun; Kang, Moo Il; Ha, Jeonghoon
- Issue Date
- 4-Apr-2022
- Publisher
- BMC
- Keywords
- Immune Checkpoint Inhibitors; Hypothyroidism; Survival; Mortality; Thyroid Function Tests
- Citation
- BMC ENDOCRINE DISORDERS, v.22, no.1
- Journal Title
- BMC ENDOCRINE DISORDERS
- Volume
- 22
- Number
- 1
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/83955
- DOI
- 10.1186/s12902-022-01004-8
- ISSN
- 1472-6823
- Abstract
- Background Immune checkpoint inhibitors (ICIs) cause thyroid immune-related adverse effects (irAEs). However, associations between each type of thyroid immune-related adverse effect (irAE) and the anti-tumor effect of ICI remains unknown. This study aimed to determine the effects of each type of thyroid dysfunction on patient survival. Methods Patients who initiated ICI treatment from January 2015 to December 2019 in Seoul St. Mary's Hospital were retrospectively analyzed. Thyroid dysfunction was classified into four types: newly developed overt or subclinical hypothyroidism, thyrotoxicosis, worsened hypothyroidism, and subclinical hyperthyroidism. Patients were divided into two groups according to the presence or absence of thyroid dysfunction. Results Among the 191 patients, 64 (33.5%) developed thyroid irAEs. There was no significant difference in age, sex, or cancer type between the two groups. The overall survival in patients with thyroid irAEs was significantly higher than that in patients without thyroid irAEs (25 months vs. 18 months, respectively, p = 0.005). After adjusting for confounding factors, the hazard ratio for mortality in the thyroid irAE group compared to the no thyroid irAE group was 0.480 (p = 0.006). Newly developed overt or subclinical hypothyroidism patients showed a significantly lower hazard ratio for mortality of 0.324 (p = 0.002). Patients with thyrotoxicosis showed a worse hazard ratio for mortality than those without thyroid irAE, although the difference was not statistically significant. Conclusions It was verified that ICI treatment-induced thyroid dysfunction was associated with better survival, even in the real-world practice. Thus, endocrinologists should cooperate with oncologists to monitor patients treated with ICIs.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.